Table 1.

Baseline characteristic of 302 patients treated with tenofovir or lamivudine

Variables	All patients	Tenofovir group	Lamivudine group
Total number of patients	302	209	93
Gender
Male	248(82%)	177(85%)	71(76%)
Female	54 (18%)	32(15%)	22(24%)
Mean age	50.78± 10	49.89± 10.704	52.80± 8.380
Male	51.45± 9.8	50.71±10.277	53.31±8.273
Female	47± 11	45.34±12.002	51.14±8.703
HBS antigen Status
HBS antigen + (n)	215	154	61
HBS antigen - (n)	87	55	32
Hbe Ag and Hbe Ab status
Hbe Ag + (n)	42	29	13
Hbe Ag – (n)	260	180	80
Hbe Ab +ve (n)	146	101	45
Hbe Ab –ve (n)	156	108	48
Anti Hbc Ab IgG
Positive (n)	201	142	59
Negative (n)	101	67	34
HBV DNA PCR
Positive (n)	148	114	34
Negative (n)	154	95	59
Number of patients who received antiviral therapy before transplantation (n)	168	125	43
Median duration of antiviral therapy before transplantation(months)		12	18
History of antiviral related side effect(s) (n, %)	2 (1.2%)	2 (1.6%)	0 (0%)